FDA holds back from action over Xeljanz safety study

The FDA has said it will wait for additional results from last week’s trial showing an increased risk of cardiac side effects with Pfizer’s arthritis blockbuster Xeljanz before deciding on

FDA sets April verdict for Pfizer’s “underestimated” atopic ...

Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert Bourla believes hasn’t been given the credit

FDA gives Lilly’s Olumiant breakthrough status for hair loss

Incyte's JAK inhibitor for GVHD fails phase 3 trial

Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another setback for a company in need of more drug successes.

Gilead says arthritis drug filgotinib fails in follow-up use...

Pfizer’s Xeljanz follow-up abrocitinib gathers momentum